Evidence map›Paper›PMID 31209520›Full record

ArticleHerz2020

Everolimus- vs. novolimus-eluting bioresorbable scaffolds in patients with acute coronary syndrome.

H M Nef, J Wiebe, G Schmidt, H Möllmann, N F Boeder, O Dörr, T Bauer, F Blachutzik, C Liebetrau, A Elsässer and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Herz, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

H M NefMedizinische Klinik I, Department of Cardiology and Angiology, University of Giessen, Klinikstraße 33, 35392, Giessen, Germany. holger.nef@innere.med.uni-giessen.de.
J WiebeDeutsches Herzzentrum Muenchen, Munich, Germany.
G SchmidtMedizinische Klinik I, Department of Cardiology and Angiology, University of Giessen, Klinikstraße 33, 35392, Giessen, Germany.
H MöllmannDepartment of Cardiology, St. Johannes Hospital, Dortmund, Germany.
N F BoederMedizinische Klinik I, Department of Cardiology and Angiology, University of Giessen, Klinikstraße 33, 35392, Giessen, Germany.
O DörrMedizinische Klinik I, Department of Cardiology and Angiology, University of Giessen, Klinikstraße 33, 35392, Giessen, Germany.
T BauerMedizinische Klinik I, Department of Cardiology and Angiology, University of Giessen, Klinikstraße 33, 35392, Giessen, Germany.
F BlachutzikDepartment of Cardiology, University of Erlangen, Erlangen, Germany.
C LiebetrauKerckhoff Heart Center, Bad Nauheim, Germany.
A ElsässerDepartment of Cardiology, University of Oldenburg, Oldenburg, Germany.
N FoinDuke-NUS Medical School, National Heart Centre Singapore, Singapore, Singapore.
C W HammMedizinische Klinik I, Department of Cardiology and Angiology, University of Giessen, Klinikstraße 33, 35392, Giessen, Germany.
University of Giessen · DECarl von Ossietzky Universität Oldenburg · DEDeutsches Herzzentrum der Charité · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEKerckhoff Klinik · DENational Heart Centre Singapore · SGSt.-Johannes-Hospital Dortmund · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLimited data exist on bioresorbable scaffolds (BRS) in patients with acute coronary syndrome (ACS). The aim of the present study was to evaluate novolimus-eluting BRS (DESolve) as interventional treatment for patients with ACS, and to compare its 12-month outcomes with the everolimus-eluting bioresorbable scaffolds (Absorb).

methodsIn this retrospective study, patients with ACS (including unstable angina pectoris, ST-segment elevation myocardial infarction, or non-ST-segment elevation myocardial infarction) treated with either the Absorb or the DESolve BRS were evaluated in a 1:1 matched-pair analysis. Major adverse cardiac events (MACE), including death, myocardial infarction, and target lesion revascularization, were evaluated as a major endpoint. The occurrence of scaffold thrombosis was also assessed.

resultsA total of 102 patients were eligible for this analysis. The rate of MACE at 12 months was comparable between the Absorb and the DESolve group (8.3% vs. 6.8%, p = 0.738). The occurrence of target lesion revascularization (6.2% vs. 4.7%; p = 0.700) and scaffold thrombosis (4.1% vs. 2.1%; p = 0.580) was comparable as well. All instances of scaffold thrombosis occurred within 30 days of the index procedure.

conclusionIn this study, similar 12-month event rates were observed for both BRS types after implantation for the treatment of ACS.

Indexed as

Acute Coronary SyndromeCardiovascular AgentsCoronary Artery DiseasePercutaneous Coronary InterventionAbsorbable ImplantsEverolimusHumansMacrolidesProsthesis DesignRetrospective StudiesTreatment OutcomeCardiovascular AgentsEverolimusMacrolidesnovolimusAbsorbable implantsCoronary artery diseaseMajor adverse cardiac eventsMyocardial ischemiaThrombosis

Identifiers

PMID31209520
OpenAlexW2949969348

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.